 I. To screen two different regimens GSK2118436 BRAFi dabrafenib as a single agent versus the combination regimen of GSK2118436 BRAFi and GSK1120212 MEKi trametinib and identify which regimen is more promising for subsequent testing in a phase III trial in radioiodine refractory BRAF-mutated differentiated thyroid cancer DTC patients. 